Matthew Lee, MD

Explore how deeper DNA/RNA testing, trial referrals, and emerging ADC combos reshape EGFR lung cancer care despite access hurdles.

Experts share how to spot and manage cancer therapy toxicities—from pneumonitis to skin and eye issues—balancing efficacy and quality of life.

How EGFR lung cancer therapies impact daily life—managing fatigue, rash, paronychia, and when to pause or reduce treatment.

Explore EGFR lung cancer next-line choices after osimertinib plus chemo—when to rechallenge platinum, use amivantamab, or try dato‑DXd.

Expert guide to sequencing EGFR lung cancer treatment after osimertinib+chemo: chemo rechallenge, amivantamab options, dato‑DXd.

Experts unpack how tumor burden, ctDNA, TP53 and patient fitness shape EGFR lung cancer therapy, and what TOP trial data means for combos.

Experts reveal how TP53 co-mutations worsen EGFR lung cancer outcomes and when to intensify first-line therapy with emerging second-line options.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss ongoing research to watch in EGFR-mutated non–small cell lung cancer

Christine Lovly, MD, PhD, and Matthew Lee, MD, detail implementation and safety considerations for subcutaneous amivantamab in EGFR-mutated NSCLC.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how the FDA approval of a subcutaneous formulation of amivantamab will affect clinical practice

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss factors that drive treatment and sequencing planning in EGFR-mutated non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.

Matthew Lee, MD, details the improved disease-free survival outcomes with adjuvant alectinib in patients with ALK-positive NSCLC.